

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8. (Cancelled)

9. (Currently Amended) ~~The A composition of claim 1~~ comprising glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol in amounts together effective to treat chronic liver disease, chronic HCV infection, or NASH in a subject, wherein the amount of glycyrrhizin is in the range of 1,000 to 1,500 mg, the amount of schisandra extract is in the range of 1,500 to 3,000 mg, the amount of ascorbic acid is in the range of 500 to 10,000 mg, the amount of L-glutathione is in the range of 50 to 1,000 mg, the amount of silymarin is in the range of 80 to 1,000 mg, the amount of lipoic acid is in the range of 150 to 1,200 mg, and the amount of d-alpha-tocopherol is in the range of 200 to 1,600 iu.

10. (Currently Amended) The composition of claim ~~1~~ 9 in capsule form.

11-15. (Cancelled)

16. (Currently Amended) ~~The A composition of claim 11~~ comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex in amounts together effective to treat chronic liver disease, chronic HCV infection, or NASH in a subject, wherein the amount of glycyrrhizin is in the range of 10 to 500 mg, the amount of ascorbic acid is in the range of 1,000 to 20,000 mg, the amount of L-glutathione is in the range of 250 to 1,500 mg, and the amount of vitamin B-complex is in the range of 0.1 to 100 ml.

17. (Currently Amended) A syringe containing the composition of claim ~~11~~ 16.

18. (Currently Amended) A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject an amount of the composition of claim ~~1~~ 9 effective to treat chronic liver disease, chronic HCV infection or NASH.

19. (Currently Amended) The method of claim 18, wherein the composition of claim ~~4~~ 9 is administered to the subject orally.

20. (Currently Amended) A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject an amount of the composition of claim ~~11~~ 16 effective to treat chronic liver disease, chronic HCV infection or NASH.

21. (Currently Amended) The method of claim 20, wherein the composition of claim ~~11~~ 16 is parenterally administered to the subject.

22. (Currently Amended) The method of claim 20, wherein the composition of claim ~~11~~ 16 is administered to the subject by infusion.

23. (Currently Amended) A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject an amount of

- (a) a first composition comprising glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, wherein the amount of glycyrrhizin is in the range of 1,000 to 1,500 mg, the amount of schisandra extract is in the range of 1,500 to 3,000 mg, the amount of ascorbic acid is in the range of 500 to 10,000 mg, the amount of L-glutathione is in the range of 50 to 1,000 mg, the amount of silymarin is in the range of 80 to 1,000 mg, the amount of lipoic acid is in the range of 150 to 1,200 mg, and the amount of d-alpha-tocopherol is in the range of 200 to 1,600 iu; and
- (b) a second composition comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, wherein the amount of glycyrrhizin is in the range of 10 to 500 mg, the amount of ascorbic acid is in the range of 1,000 to 20,000 mg, the amount of L-glutathione is in the range of 250 to 1,500 mg, and the amount of vitamin B-complex is in the range of 0.1 to 100 ml,

said amount being effective to treat chronic liver disease, chronic HCV infection or NASH.

24. (Original) The method of claim 23, wherein the first composition is administered to the subject orally.

25. (Original) The method of claim 23 or 24, wherein the second composition is parenterally administered to the subject.

26. (Original) The method of claim 25, wherein the second composition is administered to the subject by infusion.

27-34. (Cancelled)

35. (Currently Amended) The A method of claim 27 for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH, wherein 1,000 to 1,500 mg of glycyrrhizin, 1,000 to 3,000 mg of schisandra extract, 50 to 10,000 mg of ascorbic acid, 50 to 1,000 mg of L-glutathione, 80 to 1,000 mg of silymarin, 100 to 1,200 mg of lipoic acid, and 200 to 1,600 iu of d-alpha-tocopherol are administered to said subject.

36. (Currently Amended) The method of claim ~~27~~ 35, wherein the glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol are administered to the subject orally.

37-41. (Cancelled)

42. (Currently Amended) The A method of claim 37 for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH, wherein 10 to 500 mg of glycyrrhizin, 1,000 to 20,000 mg of ascorbic acid, 250 to 1,500 mg of L-glutathione, and 0.1 to 100 ml of vitamin B-complex are administered to said subject.

43. (Currently Amended) The method of claim ~~37~~ 42, wherein the glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex are parenterally administered to the subject.

44. (Original) The method of claim 43, wherein the glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex are administered to the subject by infusion.

45. (Original) A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising:

- (a) administering to the subject orally each day for 20 weeks:
 - (i) 1,000 to 1,500 mg of glycyrrhizin;
 - (ii) 1,500 to 3,000 mg of schisandra extract;
 - (iii) 500 to 10,000 mg of ascorbic acid;
 - (iv) 50 to 1,000 mg of L-glutathione;
 - (v) 80 to 1,000 mg of silymarin;
 - (vi) 150 to 1,200 mg of lipoic acid
 - (vii) 200 to 1,600 i.u. of d-alpha-tocopherol; and
- (b) parenterally administering to the subject twice a week for 10 weeks:
 - (i) 10 to 500 mg of glycyrrhizin;
 - (ii) 1,000 to 20,000 mg of ascorbic acid;
 - (iii) 250 to 1,500 mg of L-glutathione; and
 - (iv) 0.1 to 100 ml of vitamin B-complex.

46. (Original) The method of claim 45, wherein the level of free oxygen radicals in the subject is reduced.

47. (Original) The method of claim 45, wherein the level of antioxidants in the subject is increased.

48. (Original) The method of claim 45, wherein the level of adducts in the subject is reduced.

49. (Original) The method of claim 45, wherein the level of liver enzymes in the subject is normalized.

50. (Original) The method of claim 45, wherein the level of cirrhosis in the subject is reduced.

51. (Original) The method of claim 45, wherein the level of fibrosis, lobular hepatitis or periportal bridging necrosis in the subject is reduced.

52. (Currently Amended) A kit comprising:
- (a) a first container comprising a first composition comprising glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH, wherein the amount of glycyrrhizin is in the range of 1,000 to 1,500 mg, the amount of schisandra extract is in the range of 1,500 to 3,000 mg, the amount of ascorbic acid is in the range of 500 to 10,000 mg, the amount of L-glutathione is in the range of 50 to 1,000 mg, the amount of silymarin is in the range of 80 to 1,000 mg, the amount of lipoic acid is in the range of 150 to 1,200 mg, and the amount of d-alpha-tocopherol is in the range of 200 to 1,600 iu; and
 - (b) a second container comprising a second composition comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH, wherein the amount of glycyrrhizin is in the range of 10 to 500 mg, the amount of ascorbic acid is in the range of 1,000 to 20,000 mg, the amount of L-glutathione is in the range of 250 to 1,500 mg, and the amount of vitamin B-complex is in the range of 0.1 to 100 ml.
53. (Currently Amended) The kit of claim 52, wherein the second container is a syringe.
54. (Currently Amended) A kit comprising a container comprising the composition of claim ~~4~~ 9.
55. (Currently Amended) A kit comprising a container comprising the composition of claim ~~44~~ 16.
56. (Cancelled)
57. (New) The composition of claim 9, wherein the glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol are in amounts together effective to treat chronic HCV infection.

58. (New) The composition of claim 10, wherein the glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol are in amounts together effective to treat chronic HCV infection.

59. (New) The composition of claim 16, wherein the glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex are in amounts together effective to treat chronic HCV infection.

60. (New) The composition of claim 17, wherein the glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex are in amounts together effective to treat chronic HCV infection.

61. (New) The method of claim 18 for treating chronic HCV infection.

62. (New) The method of claim 19 for treating chronic HCV infection.

63. (New) The method of claim 20 for treating chronic HCV infection.

64. (New) The method of claim 21 for treating chronic HCV infection.

65. (New) The method of claim 22 for treating chronic HCV infection.

66. (New) The method of claim 23 for treating chronic HCV infection.

67. (New) The method of claim 24 for treating chronic HCV infection.

68. (New) The method of claim 25 for treating chronic HCV infection.

69. (New) The method of claim 26 for treating chronic HCV infection.

70. (New) The method of claim 35 for treating chronic HCV infection.

71. (New) The method of claim 36 for treating chronic HCV infection.

72. (New) The method of claim 42 for treating chronic HCV infection.

73. (New) The method of claim 43 for treating chronic HCV infection.

74. (New) The method of claim 44 for treating chronic HCV infection.

75. (New) The method of claim 45 for treating chronic HCV infection.
76. (New) The kit of claim 52, wherein the first composition of the first container comprises glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol in amounts together effective to treat chronic HCV infection, and wherein the second composition of the second container comprises glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex in amounts together effective to treat chronic HCV infection.
77. (New) The kit of claim 53, wherein the first composition of the first container comprises glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol in amounts together effective to treat chronic HCV infection, and wherein the second composition of the second container comprises glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex in amounts together effective to treat chronic HCV infection.
78. (New) The kit of claim 54, wherein the composition comprises glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol in amounts together effective to treat chronic HCV infection.
79. (New) The kit of claim 55, wherein the composition comprises glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex in amounts together effective to treat chronic HCV infection.